European Pharmaceutical Review

NOVEMBER 2, 2022

The clinic will develop pre-clinical studies into early and late phase clinical trials to identify US Food and Drug Administration (FDA)-approved advanced regenerative medicines. The organisation considers collaboration will advance scientific discovery, clinical advances and training.

Food and Drug Administration 86

Food and Drug Administration Medicine Training Electronics 86

Pharmaceutical Technology

MAY 9, 2023

Biotechnology company Neuro3 Therapeutics has signed an exclusive worldwide licence and option agreement with pharmaceutical firm Lundbeck to develop and commercialise clinical stage KCNQ2 activators. The company will also handle the further development of these programmes through clinical proof-of-concept (PoC).

Pharmaceutical 52

Pharmaceutical 52

Pharmaceutical Technology

AUGUST 1, 2022

GreenLight Biosciences has entered a partnership with the US National Institutes of Health (NIH) for the development of Covid-19 vaccines, which offer broader protection against new variants and with durable effects. They intend to develop vaccines that provide lasting immune responses compared to existing vaccines.

Marketing 98

Marketing Pharmaceutical Manufacturing 98

Pharmaceutical Technology

MAY 12, 2023

Angelini Pharma has entered an exclusive global development and commercialisation deal with JCR Pharmaceuticals to develop and commercialise new biologic therapies to treat epilepsy. in additional development and commercial milestone payments. It will also be entitled to receive tiered royalties.

Pharma 52

Pharma Pharmaceutical Patients 52

Clarivate

OCTOBER 19, 2023

De-novo drug discovery and development pipelines are time-consuming and costly. It can take up to 17 years and cost more than $2 billion dollars from the discovery of a new drug until it reaches the market. The most important benefit is that it can deliver efficacious therapeutics to patients awaiting treatment much faster.

Networking 59

Networking Consulting Safety Side effects 59

Pharmaceutical Technology

OCTOBER 11, 2022

Biotechnology company Ochre Bio has raised $30m in a Series A financing round to develop RNA therapies for chronic liver diseases. The company stated that the results from the human liver pre-clinical testing next year will inform the therapies that will advance into clinical tests in 2024.

Medicine 52

Medicine Pharmaceutical Patients 52

European Pharmaceutical Review

JANUARY 4, 2024

Prophylactic treatment as a preventative measure The new study, published in Blood Cancer Discovery , stated that in the future, this could eliminate the need to administer teclistamab and other immunotherapies in hospitals. “In Data showed that only 13 percent of the patients developed CRS after prophylactic treatment with tocilizumab.

Side effects 78

Side effects Food and Drug Administration Patients Medicine 78

pharmaphorum

OCTOBER 7, 2022

With new technologies such as CryoEM and DNA encoded libraries showing promise, join us as we take a deep dive into the key challenges holding back the progression of candidates into pre-clinical studies by determining the best technologies and methodologies for your programs. View the full event guide here.

Medical 52

Medical Pharmaceutical Pharma 52

pharmaphorum

MAY 27, 2022

This year’s re-imagined agenda will cover unique target discovery, mechanistic diversity and translational science as well as novel formats, product design and manufacturability challenges faced in the bispecific field. Download the Full Event Guide here for speakers, presentations, pricing and more.

Engineering 52

Engineering Manufacturing Patients 52

Pharma Leaders

APRIL 12, 2023

ImmuneBridge is developing allogeneic NK cell-based immunotherapies to treat solid tumours and hematologic malignancies. The company’s orthogonal approach leverages an expansion technology and a diverse clinic-ready source for accelerating the discovery and translation of potent cell therapies.

Engineering 52

Engineering Manufacturing Medicine Management 52

MedCity News

JUNE 16, 2023

Investors in 2022 appeared confident that the continued transformation of drug research and development protocols and the overall life sciences industry will not only include digital health solutions, but will even depend on them for data collection, analysis, patient engagement, and even their therapeutic properties. digital health at $17.7

Pharma 108

Pharma Food and Drug Administration Recruitment Pharmacology 108

European Pharmaceutical Review

JANUARY 12, 2024

Levy is a leading life sciences expert who has published multiple articles on drug development and technology trends. Prior to joining Clarivate, Levy held several roles in the pharmaceutical industry, including at Veeva Systems, Pharmaceutical Product Development (PPD) and Accenture.

Pharma 78

Pharma Pharmaceutical Recruitment Pharmaceutical products 78

World of DTC Marketing

SEPTEMBER 9, 2021

Chan School of Public Health, says, “at the moment, people are skeptical enough of the pharmaceutical industry that they’re going to have a tough time saying that if the government gets you a discount, you won’t get discoveries.”. If pharma is a business, they will find a way to develop, buy, or acquire new drugs.

Healthcare 222

Healthcare Healthcare Government Insurance 222

European Pharmaceutical Review

AUGUST 18, 2022

Merck (MSD outside of the US and Canada) has entered into a collaboration agreement with Orna Therapeutics to discover, develop and commercialise multiple programmes of engineered circular RNA (oRNA) therapies, including vaccines and therapeutics in the areas of infectious disease and oncology.

Engineering 89

Engineering Manufacturing Medicine Sales 89

pharmaphorum

NOVEMBER 9, 2022

A pre-clinical pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial permeability pore (mPTP) are to be developed. Inhibition of the mPTP has been shown, however, to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models.

Medicine 52

Medicine Management Medical Patients 52

European Pharmaceutical Review

MAY 2, 2023

3 With greater scientific understanding of cancer, the industry has made significant progress in developing innovative medicines to help patients. the average duration to develop a new medicine is still around 10-15 years We know that the research and development (R&D) process behind developing new medicines is increasingly complex.

Patients 101

Patients Medicine Marketing Medical 101

pharmaphorum

JULY 26, 2022

The 5th Annual Targeted Protein Degradation Summit returns to Boston as the most comprehensive, definitive event of the year, uniting 700+ large pharma, innovative biotech and world-renowned academics to discuss the full breadth of protein degrader drug development.

Networking 52

Networking Safety Pharma 52

pharmaphorum

JUNE 28, 2022

The 2022 Conference theme is on the latest advances in oligonucleotide discovery and delivery. Listen to case studies presenting on pre-clinical and clinical research in areas such as oncology and what can be learned for future clinical trials. By attending the conference attendees will have the opportunity to.

Media 52

Media Engineering Consulting Networking 52

pharmaphorum

DECEMBER 20, 2022

In recent years, those involved in the research and development of new oncology treatments have delivered ground-breaking therapies. ADCs have also been developed to become more effective, whilst being better able to preserve healthy cells. Cancer is the major therapeutic focus area for the pharmaceutical industry.

Leads 75

Leads Patients Recruitment Consulting 75

European Pharmaceutical Review

NOVEMBER 3, 2022

Speaking live from CPhI Frankfurt , Christian Roghi, Director of Microbiome Solutions, predicted microbiome therapy will be the next big breakthrough in novel therapies, rivalling discoveries like mABs, siRNA and CAR T cells. “We We are seeing huge interest in microbiome research, especially in the last five years. diff infection.

Safety 83

Safety Patients Pharmaceutical Marketing 83

Pharmaceutical Technology

OCTOBER 13, 2022

Vita Therapeutics has raised $31m in a Series B financing round for the development of cell therapies for neuromuscular diseases and cancers. Vita Therapeutics intends to use the funding to advance its lead pre-clinical programme VTA-100 for limb-girdle muscular dystrophy (LGMD2A) to clinical trials.

Biopharma 52

Biopharma Pharmaceutical Patients Leads 52

Medico Reach

DECEMBER 2, 2022

To bring effective medicines and Innovations in healthcare industry , a Clinical Research Organization or Contract Research Organization (CRO) are a must for the Biotech, Medtech, and pharma industries. In 2022, the global clinical research market stands at $63.6 Pharmaceutical Product Development (PPD). from 2022 to 2027.

Consulting 98

Consulting Specialization Medicine Medical 98

Pharmaceutical Technology

APRIL 6, 2023

Ginkgo Bioworks has strengthened its end-to-end R&D capabilities in gene therapy with the purchase of adeno-associated virus (AAV) capsid discovery and engineering assets from StrideBio, for an undisclosed sum. The new capabilities and IP will be incorporated under Ginkgo’s end-to-end AAV gene therapy development platform.

Engineering 52

Engineering Safety Manufacturing Leads 52

pharmaphorum

OCTOBER 26, 2022

The stream of novel targets will leverage the proprietary discovery platforms of Normunity’s scientific founder Dr Lieping Chen, an immuno-oncologist who was one among other contributors within the field to identify PD-L1 (B7-H1). The emerging targets will be interrogated and validated together pre-clinically and clinically.

Medicine 52

Medicine Leads Medical Patients 52

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. According to GlobalData, Phase III drugs for Paroxysmal Nocturnal Hemoglobinuria have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration.

Prescription 40

Prescription Pharmaceutical products Networking Pharmaceutical 40

Pharmaceutical Technology

FEBRUARY 28, 2023

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Glomerulonephritis. According to GlobalData, Phase III drugs for Glomerulonephritis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. Buy the report here.

Prescription 40

Prescription Pharmaceutical products Networking Pharmaceutical 40

PM360

NOVEMBER 29, 2022

When developing content for new drug labels, life sciences companies’ regulatory teams face challenges in gathering intelligence to better understand competitive factors, market dynamics, and effective approval strategies. Understanding patient sub-group exceptions for competitive or for label development purposes.

Food and Drug Administration 98

Food and Drug Administration Competition Safety Pharmacology 98

Pharmaceutical Technology

JUNE 24, 2022

GlaxoSmithKline (GSK) has announced plans to invest $1.2bn (£1bn) over a decade to expedite research and development (R&D) for infectious diseases in lower-income countries. These options include R&D on long-acting injectables that could protect against P. falciparum malaria.

Pharmaceutical 59

Pharmaceutical Medicine Healthcare Healthcare 59

PM360

JANUARY 5, 2024

The Omega collaboration will leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management. Novo Nordisk, Omega Therapeutics, Inc. and Cellarity Inc.

Medicine 52

Medicine Management Patients Sales 52

pharmaphorum

OCTOBER 9, 2018

The journey from molecule discovery and development through valuation, funding, regulatory and commercialisation can be a long and complex road to travel though. Now more than ever before, Biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.

Marketing 52

Marketing Engineering Medicine Patients 52

pharmaphorum

OCTOBER 28, 2022

The sooner a human-centred perspective is applied to the development of either a drug or device product, the more likely the product will be adopted and used because it’s been designed around what the end consumer wants and needs. Could this candidate demonstrate clinical efficacy?

Physicians 81

Physicians Marketing Patients Recruitment 81

Clarivate

NOVEMBER 14, 2023

1] And, sometimes, it’s the small, incremental developments that provide the most benefit. That being said, these incremental changes would not be possible without the more radical ‘game-changers’, which provide the starting point for further development.

Food and Drug Administration 52

Food and Drug Administration Medicine Patients Food 52

pharmaphorum

SEPTEMBER 27, 2022

However, it is only with recent advances in the scientific community’s knowledge of the immune suppressive mechanisms that cancer cells employ that has allowed the technology behind cancer vaccines to develop rapidly. The science around the area has existed for a long time.

Leads 70

Leads Sales Patients Pharma 70

Legacy MEDSearch

JANUARY 11, 2023

As a result, Micronoma can expect continued guidance and prioritized reviews from the agency of its upcoming clinical trial and concomitant pre-market approval processes. These discoveries were then validated in a large, lung-specific cohort, as described in a manuscript shared with the FDA and under review at a high-impact journal.

FDA 52

FDA Food and Drug Administration Recruitment Patients 52

Impetus Digital

JANUARY 13, 2023

The idea was that you have almost like an agreement to pre-purchase clinical trial data and that acts as a pool incentive. Here is a sneak peek of our conversation: Q: You started the company as a charity. How did it go and why did it go from a charity to an actual company? A: The idea, as I mentioned, came from my thesis.

Professional Services 52

Professional Services Healthcare Provider Consulting Healthcare 52

Impetus Digital

NOVEMBER 3, 2022

DarioHealth is focused on having one integrated multi-chronic condition platform for members to be able to help them manage their chronic conditions, change their behavior over a period of time, and therefore improve the clinical results that we see with those members. It really moves and responds to what they’re interested in doing.

Management 52

Management Pharma Patients Professional Services 52

Clarivate

APRIL 6, 2022

Peer reviewers and editors are gatekeepers of the research literature used to document and communicate human discovery. Learning to peer review is also an important step in improving your own professional development. How to write a peer review. It will also help you identify potential breaches of normal ethical practice.

Training 98

Training Ethics Networking Government 98